A randomized, double-blind, placebo-controlled, crossover study of the efficacy of omalizumab in patients with aspirin-exacerbated respiratory disease (AERD)
Not Applicable
- Conditions
- Aspirin exacerbated respiratory disease (AERD)
- Registration Number
- JPRN-UMIN000018777
- Lead Sponsor
- Sagamihara National Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
1) Previous treatment with omalizumab 2) Unable to provide written, signed and dated informed consent 3) Patients considered at risk of sinusitis and/or nasal polyp surgery during the study period 4) Patients with comorbidities (renal, hepatic, heart, mental, and malignancy) requiring treatment 5) Pregnancy, breast-feeding, or potential pregnancy 6) Patients considered unsuitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method